Doctor of Podiatric Medicine Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Bradley Newswander

Podiatrist Gilbert, AZ Doctor of Podiatric Medicine

NPI 1740254036 CMS profile 351057

5656 S Power Rd Ste 124, Gilbert, AZ 85295

Open in the dashboard

General payments

$3,156

86 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Bradley Newswander of Gilbert, AZ is reported in the CMS Open Payments database as having received $3,156 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,495 16
2023 General $283 11
2022 General $422 20
2021 General $535 21
2020 General $214 11
2019 General $207 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradley Newswander
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Bradley Newswander were reported at $0. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Bradley Newswander Podiatrist median Middle half National median
2019 $207 $196 $72–$601 $163
2020 $214 $118 $38–$335 $114
2021 $535 $169 $57–$573 $132
2022 $422 $220 $74–$782 $149
2023 $283 $208 $71–$635 $160
2024 $1,495 $237 $87–$681 $164
2025 $0 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Fusion Orthopedics USA, LLC $1,138 1 payment
  2. Smith+Nephew, Inc. $487 24 payments
  3. Vaporox, Inc. $272 4 payments
  4. Dynasplint Systems Inc. $125 3 payments
  5. Djo, LLC $108 5 payments
  6. Nevro Corp. $98 1 payment
  7. Horizon Therapeutics plc $98 6 payments
  8. AbbVie, Inc. $90 4 payments
  9. Bioventus LLC $86 5 payments
  10. Medtronic Vascular, Inc. $85 1 payment
  11. Other $570 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,907 83 payments
  2. Consulting Fee $1,138 1 payment
  3. Gift $100 1 payment
  4. Education $12 1 payment
Products named General payments · program years 2019–2024
  1. GRAFIX $262 9 payments
  2. STRAVIX PL $164 4 payments
  3. OASIS $139 2 payments
  4. Dynasplint $125 3 payments
  5. Senza $98 1 payment
  6. KRYSTEXXA $98 6 payments
  7. DALVANCE $90 4 payments
  8. HawkOne $85 1 payment
  9. ORTHOLOC $73 2 payments
  10. CMF $70 3 payments
  11. Other $804 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

519

Median for Podiatry: 160

Drug cost

$6,456

Median for Podiatry: $2,368

Branded share of claims

32%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Ciclopirox Olamine Brand 51 $1,069
Celecoxib Generic 104 $1,009
Ketoconazole Generic 23 $917
Gabapentin Generic 78 $810
Doxycycline Hyclate Generic 55 $724
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 37 $501
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $285
Ondansetron Odt Ondansetron Brand 22 $245
Mupirocin Generic 14 $236
Triamcinolone Acetonide Generic 13 $221

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$488,936

Of which drugs: $310,452

Medicare patients

368

Average age 76

Services billed

3,951

208 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 39%
Ischemic heart disease 38%
Chronic kidney disease 36%
Atrial fibrillation 26%
Depression 19%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 50 128 $100
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 65 257 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record